US lawsuit may not impact India launch of Gennova's mRNA vaccine

The vaccine is now under review by the regulator, and if approved, it may be ready for launch in the Indian market and will be the first mRNA Covid vaccine to be available here.

The lawsuit in a Seattle court by a US start-up may not immediately impact the launch of Pune-based Gennova Biopharmaceuticals’ mRNA vaccine HGCO19 once it receives the Indian regulator’s nod, feel legal experts.

The long-term prospects of the vaccine may depend on how the case progresses. Gennova already submitted phase 2/3 clinical trial data with the Drugs Controller General of India (DCGI) this month.

The vaccine is now under review by the regulator, and if approved, it may be ready for launch in the Indian market. It will be the first mRNA Covid vaccine to be available here.

Meanwhile, US firm HDT Bio